Millipore Sigma Vibrant Logo

382185 HDAC Inhibitor XXII, NCH51 - CAS 848354-66-5 - Calbiochem

382185
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

Empirical FormulaCAS #
C₂₀H₂₆N₂O₂S₂ 848354-66-5

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
382185-2MG
Récupération des données relatives à la disponibilité...
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Flacon en verre 2 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA's hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
      Catalogue Number382185
      Brand Family Calbiochem®
      SynonymsThioisobutyric acid (S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
      References
      ReferencesSanda, T., et al. 2007. Leukemia 21, 2344.
      Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
      Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.
      Product Information
      CAS number848354-66-5
      FormWhite powder
      Hill FormulaC₂₀H₂₆N₂O₂S₂
      Chemical formulaC₂₀H₂₆N₂O₂S₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Application Comments#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Regulatory Review
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      HDAC Inhibitor XXII, NCH51 - CAS 848354-66-5 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      382185

      Références bibliographiques

      Aperçu de la référence bibliographique
      Sanda, T., et al. 2007. Leukemia 21, 2344.
      Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
      Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-November-2011 RFH
      SynonymsThioisobutyric acid (S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
      DescriptionA cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA's hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
      FormWhite powder
      CAS number848354-66-5
      Chemical formulaC₂₀H₂₆N₂O₂S₂
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Comments#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Regulatory Review
      ReferencesSanda, T., et al. 2007. Leukemia 21, 2344.
      Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
      Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.